



## Araştırma Makalesi /Research Article

Journal of Medical Topics & Updates (Journal of MTU)

Doi: 10.58651/jomtu.1389734

### COVID-19-associated morbidity and mortality outcomes in pregnant patients admitted to intensive care unit

### Yoğun bakım ünitesine kabul edilen hamile hastalarda COVID-19 ilişkili morbidite ve mortalite sonuçları

Ahmet AYDIN<sup>1</sup> Sevgi KUTLUSOY<sup>1</sup> Erdiñç KOCA<sup>1</sup>

Malatya Turgut Ozal University, Department of Anesthesiology and Reanimation Clinic, Malatya Training and Research Hospital. Malatya, Türkiye.

#### ABSTRACT

**Background:** Our study aimed to evaluate the clinical characteristics and maternal-fetal outcomes of pregnant women admitted to the ICU due to COVID-19 pneumonia.

**Materials and Methods:** Demographic data, presenting complaints, laboratory values, pregnancy outcomes, delivery method, and ICU mortality were recorded.

**Results:** A total of 10 pregnant patients were admitted to the intensive care unit of our hospital due to SARS-COV-2 infection during the 2-year period. Arterial blood oxygen saturation values measured at admission to the ICU were higher in the surviving patients. Six of the 10 patients died. Only one of the 7 patients requiring invasive mechanical ventilation survived.

**Conclusions:** We found that COVID-19-infected pregnant women with severe symptoms have several maternal morbidities and poor obstetric outcomes, such as prolonged intensive care unit stay, increased mortality, neonatal deaths, and cesarean section.

**Keywords:** Acute respiratory distress syndrome, COVID-19, Maternal outcomes, Obstetric outcomes

#### ÖZET

**Amaç:** Çalışmamız, yoğun bakım ünitesine COVID-19 pnömonisi nedeniyle yatırılan gebe kadınların klinik özelliklerini ve anne-fetal sonuçlarını değerlendirmeyi amaçladı.

**Materyal ve Metot:** Demografik veriler, başvuru şikayetleri, laboratuvar değerleri, gebelik sonuçları, doğum şekli ve yoğun bakım mortalitesi kaydedildi.

**Bulgular:** 2 yıllık süreçte SARS-COV-2 enfeksiyonu nedeniyle hastanemizin yoğun bakım ünitesine toplam 10 hamile hasta yatırıldı. Yaşayan hastalarda yoğun bakım ünitesine girişte ölçülen arteriyel kan oksijen saturasyonu değerleri daha yüksekti. 10 hastadan 6'sı hayatını kaybetti. İnvazif mekanik ventilasyon gerektiren 7 hastadan sadece biri hayatta kaldı.

**Sonuç:** Şiddetli semptomları olan COVID-19 ile enfekte hamile kadınlarda, uzamış yoğun bakım ünitesinde kalış süresi, artmış mortalite, yenidoğan ölümleri ve sezaryen gibi kötü obstetrik sonuçlar ve maternal morbiditelerin olduğunu tespit ettik.

**Anahtar Kelimeler:** Akut respiratuvar distres sendromu, COVID-19, Anne sonuçları, Obstetrik sonuçlar

Geliş Tarihi / Received: 12.11.2023, Kabul Tarihi / Accepted: 08.04.2024

Sorumlu Yazar / Corresponding Author: Department of Anesthesiology and Reanimation Clinic, Malatya Turgut Ozal University. Malatya Training and Research Hospital. Malatya, Türkiye. e-mail: ketamin2323@gmail.com

## INTRODUCTION

The SARS-CoV-2 pandemic, which first emerged in 2019 and has become a serious public health problem, is still ongoing worldwide. The clinical picture of patients infected by the virus may be mild or may progress to a clinical condition that may lead to acute respiratory distress syndrome (ARDS) and death (Zhonghua Liu Xing Bing Xue Za Zhi, 2020; Huang C, et al.,2020). Previous studies reported that pregnant women with COVID-19 are at high risk of severe disease and maternal mortality (Ellington S et al.,2020; Allotey J et al., 2020).

Alterations in the respiratory system result in a predisposition for the progression of infections to severe disease in pregnant women. During pregnancy, the diaphragm rises by about 4 cm due to the uterus, and the functional residual capacity (FRC) decreases by up to 30%. Alterations in the respiratory system that occur are more pronounced in the third trimester. The decrease in the residual capacity causes dyspnea, which becomes more severe, particularly in the third trimester. COVID-19-associated pneumonia in pregnant women is considered a risk factor for adverse outcomes such as perinatal death, preterm delivery, and cesarean delivery in all pregnant women, particularly in the third trimester (Di Mascio D et al., 2020; Chen H et al., 2020; Hui DSC, Zumla A, 2019; Wastnedge EAN et al., 2021; LoMauro A, Aliverti A, 2015). In the SARS-CoV-1 and MERS-CoV pandemics, it was shown that 50% of pregnant women developing severe acute respiratory syndrome (SARS) were admitted to intensive care units with a mortality rate of up to 25%. In the COVID-19 pandemic, it was found that 9.6% of the infected pregnant women were admitted to intensive care units, with a maternal mortality rate of 1.6% (Wong SF, et al.,2004; Turan O, et al.,2020 ).

Our study aimed to evaluate the clinical characteristics and maternal-fetal outcomes of pregnant women admitted to the intensive care unit (ICU) due to COVID-19 pneumonia. Our study also aimed to provide related data to clinicians and for future studies.

## MATERIALS AND METHODS

Our study was a retrospective, single-center study, and all procedures of the study were performed in compliance with the Helsinki Declaration. Our study included pregnant or postpartum patients aged 18 years or older who required intensive care due to COVID-19 pneumonia between March 1, 2020 and March 31, 2022. The study excluded pregnant women with immunological deficiencies and individuals with negative COVID-19 PCR results. Our ICU was a tertiary care intensive care unit with 42 beds. Patient data were collected from

the hospital's medical record system and patient charts. The demographic data, time from PCR positivity to hospital admission, presenting complaints, comorbidities, high-flow nasal cannula (HFNC) requirement, time from ICU admission to intubation, peripheral oxygen saturation (SpO<sub>2</sub>), laboratory values, pregnancy outcomes, delivery method (cesarean section, normal vaginal delivery), invasive mechanical ventilation (IMV) requirement, ICU mortality, and length of stay (LOS) in ICU were recorded. SARS COV-2 variant identification was unknown.

Disease severity was assessed according to oxygenation: mild ARDS, 200 mmHg < PaO<sub>2</sub>/FiO<sub>2</sub> ≤ 300 mmHg with PEEP/CPAP ≥ 5 cmH<sub>2</sub>O; moderate ARDS, 100 mmHg < PaO<sub>2</sub>/FiO<sub>2</sub> ≤ 200 mmHg with PEEP ≥ 5 cmH<sub>2</sub>O; and severe ARDS, PaO<sub>2</sub>/FiO<sub>2</sub> ≤ 100 mmHg with PEEP ≥ 5 cmH<sub>2</sub>O (ARDS Definition Task Force; Ranieri VM, et al.,2012). The use of prone positioning, vasopressors, and inotropes was evaluated. All ICU-admitted pregnant patients were consulted by an obstetrician and a perinatologist.


Patients with ongoing pregnancy were administered lopinavir/ritonavir as an antiviral treatment based on the COVID-19 Treatment Guidelines of the Turkish Ministry of Health. The patients whose pregnancies ended received favipiravir. All patients were unvaccinated.

The clinical courses of the patients after ICU admission are presented separately for each patient. The reasons for the pregnancy outcomes (obstetric reasons/Covid-19-related maternal problems) are presented. The pregnancy outcomes of patients with ongoing pregnancy were followed up. Our study was granted ethics approval by the Ethics Committee for Non-interventional Studies of X University with Approval No. 2021/118.


Data were analyzed using the Statistical Package for the Social Sciences (SPSS) Version 21.0 (IBM Corp, Armonk, NY, USA.). Continuous variables were presented as median, as appropriate. Categorical data are presented as frequencies (n) and percentages (%). The Mann-Whitney U test was used for continuous variables, as appropriate.  $p < 0.05$  was considered statistically significant.

## RESULTS

A total of 10 pregnant patients were admitted to the intensive care unit of our hospital because of SARS-CoV-2 infection during the 2-year period. The median age of the patients was 29.5 years. The demographics and clinical characteristics of the patients are presented in Table 1, 2. The flowchart of all patients is presented in Figures 1 and 2.



**Figure 1.** Flow chart of survivors



**Figure 2.** Flowchart of nonsurvivors

The main presenting complaints were cough, malaise/fatigue, and respiratory failure. Six of the 10 patients died (Table 1). The median age of non-surviving pregnant women was 31.5 years. The presenting complaint of most non-surviving patients

was respiratory failure. High-flow nasal oxygen treatment was required in 6 patients at admission. Only one of these 6 patients survived. Three patients received only supplemental oxygen with a reservoir mask (6-15 L/min).

**Table 1.** Demographic and clinical characteristics of pregnant women with COVID-19

	All Patients (n=10)	Survivors (n=4)	Non-Survivors (n=6)	p values
Median Age (IQR), (min/max)	29.5 (18/40)	28.5 (27/36)	31.5 (18/40)	0.670
LOS (median, min/max)	10.5 (4/23)	5 (4/23)	14.5(4/23)	0.328
Time to apply to hospital (days) (median, min/max)	5 (3/7)	4.5 (3/7)	5 (4/6)	0.507
Gestational Age (week) (Median) (min/max)	27.5 (6/38)	30.5 (6/36)	26.5(22/38)	1.000

$p < 0.05$ ; Mann-Whitney U test; IQR: Interquartile Range; LOS: Length Of Stay

**Table 2.** Clinical characteristics of pregnant women with COVID-19

Signs and Symptoms	All Patients (n=10)	Survivors (n=4)	Non-Survivors (n=6)
Fever (n, %)	1(10)	1 (25)	-
Cough (n, %)	8 (80)	4 (100)	4 (66.6)
Fatigue (n, %)	7 (70)	4 (100)	3 (50)
Headache (n, %)	2 (20)	2 (50)	-
Respiratory Failure (n, %)	7 (70)	1 (25)	6 (100)
Pregnancy outcome	All Patients (n=10)	Survivors (n=4)	Non-Survivors (n=6)
Spontaneous abortion (n, %)	1 (10)	1 (25)	
Cesarean section (CS) (n, %)	6 (60)	2 (50)	4 (66.6)
Due to obstetrical indications (CS) (n, %)	3 (30)	1 (25)	2 (33.3)
Due to concern about Covid-19 (CS) (n, %)	3 (30)	1 (25)	2 (33.3)
Neonatal Death (n, %)	2 (20)		2 (33.3)
Perinatal Death (n, %)	1 (10)		1 (16.6)
Pregnancy ongoing (n, %)	2 (20)	2 (50)	
Vaginal delivery (n, %)		1 (25)	
Cesarean section (CS) (n, %)		1 (25)	

Only one of the 7 patients requiring invasive mechanical ventilation survived. This patient was at 6-weeks of gestation and her pregnancy ended in spontaneous abortion. The patient was considered to have cytokine storm and tocilizumab was administered. Upon deterioration in consciousness and development of desaturation on the third day of intensive care stay, the patient was electively intubated and MV was set to achieve a PEEP of 10 cmH<sub>2</sub>O and a FiO<sub>2</sub> of 100 percent. Intermittent prone positioning was performed. The patient was weaned from MV on day 17 of the intensive care unit stay and was discharged on day 23 of the intensive care unit. The patient was discharged with full recovery afterward follow-up.

Because the other surviving patients did not exhibit respiratory distress or an increase in oxygen demand during the intensive care follow-ups, two patients were taken to the service on the fifth day of intensive

care hospitalization and one patient on the fourth day.

The clinical status of 6 patients who did not survive was consistent with severe ARDS (PaO<sub>2</sub>/FiO<sub>2</sub> ≤ 100 mmHg). These patients intermittent prone positioning was performed. HFNC was initiated or intermittent non-invasive ventilation (NIV) was administered to all patients according to their clinical status. Three patients required invasive mechanical ventilation on day 3 of the intensive care unit stay. Invasive mechanical ventilation was performed in two patients on the fourth day and in one patient on the eighth day. Norepinephrine infusion was initiated in all hypotensive patients to keep the mean arterial pressure above 60 mmHg. Despite all efforts, two patients died on the 23rd day, one on the 14th day, one on the 15th day, one on the 7th day, and one on the 4th day.

The pregnancy outcomes are presented in Table 2. The pregnancies of two out of 4 surviving patients were ongoing after discharge. The post-discharge follow-ups of these patients were reviewed. One patient had normal a vaginal delivery at 38 weeks of gestation (10 weeks later). The other patient underwent a cesarean section due to obstetric indications during the ward stay at 36 weeks of gestation. No problems were observed in these infants. Of the other surviving patients, one had a

stillbirth, and the other was admitted to the ICU following cesarean section.

The pregnancy outcomes of the patients who were nonsurvivors were as follows. In three patients, three live babies were delivered via cesarean section. A dead baby weighing 920 g was delivered by cesarean section in one patient. Obstetric examination revealed no fetal heartbeat in one patient. One patient had a spontaneous vaginal delivery.

**Table 3.** Laboratory findings of pregnant women with COVID-19

	All Patients (n=10)	Survivors (n=4)	Non-Survivors (n=6)	p values
Glucose (mg/dL)	110 (84/169)	108.5 (101/114)	121.5 (84/169)	0.336
Urea (mg/dL)	21.5 (7.2/83)	25 (7.2/83)	20 (8.5/34)	0.670
Creatinine (mg/dL)	0.58 (0.4/1.86)	0.63 (0.5/1.86)	0.56 (0.4/0.7)	0.240
AST (U/L)	32 (18/79)	33 (25/50)	28.5 (18/79)	0.520
ALT (U/L)	24 (16/47)	29 (24/47)	22 (16/39)	0.281
LDH (U/L)	330 (237/996)	488 (272/996)	323 (237/859)	0.522
Sodium (mmol/L)	137 (125/141)	136 (125/138)	138 (133/141)	0.185
Potassium (mmol/L)	3.7 (3.06/5.4)	3.5 (3.06/4.3)	3.9 (3.3/5.4)	0.286
CRP (mg/dL)	5.8 (4.1/9.7)	6.8 (5.3/9.7)	5.14 (4.1/8.1)	0.201
WBC (10 <sup>3</sup> /uL)	11 (5/21.6)	10 (8.4/21.6)	12.7 (5/19)	0.831
Hemoglobin (g/dL)	11.3 (9.7/13.5)	11.7 (11.3/12.8)	10.7 (9.7/13.5)	0.199
Hematocrit (%)	33.8 (30.5/39)	34.8 (33.7/37.7)	32.9 (30.5/39)	0.201
Neutrophil (10 <sup>3</sup> /uL)	10 (4.1/18)	8.87 (6.8/18)	11.2 (4.1/17.2)	0.831
Lymphocyte (10 <sup>3</sup> /uL)	1.05 (0.36/2.37)	1.24 (0.3/2.3)	0.98 (0.5/2)	0.522
Ferritin	212.5 (33/2000)	345 (85/714)	144 (33/2000)	0.394
Procalcitonin	0.18 (0.05/7.9)	0.13 (0.08/7.9)	0.2 (0.05/2.6)	0.669
D-dimer	2.6 (0.21/12.6)	7.74 (1.4/12.6)	0.67 (0.2/7.9)	0.088
Saturation % (in blood gas)	90.5 (80/98)	98 (90/98)	89.5 (75/96)	<b>0.040</b>
Lactate (mmol/L) (in blood gas)	2.25 (0.8/3)	1.95 (1.1/3)	2.4 (0.8/3)	0.830

Median (min/max),  $p < 0.05$ ; Mann-Whitney U test; AST: Aspartate aminotransferaz; ALT: Alanine aminotransferase; LDH: Lactate dehydrogenase; WBC: White blood cell

The laboratory values are given in Table 3. Arterial blood oxygen saturation values measured at admission to the ICU were higher in the surviving patients ( $p=0.04$ ). Six patients received antiviral treatment. Only two of the patients receiving antiviral treatment survived.

One patient underwent left tube thoracostomy due to pleural effusion, one patient received thrombolytic treatment due to pulmonary embolism, and one patient required renal replacement therapy.

## DISCUSSION

The data presented here represent pregnant women admitted to the intensive care unit in a single center. It was reported that in pregnant women infected with Covid-19, the clinical course and severity of the disease were worse than in nonpregnant women. A surveillance study showed that negative maternal outcomes were more commonly seen at the end of the second trimester and in the third trimester of pregnancy (DeBolt CA, et al. 2021; Knight M, et al.

2020). Our study also observed that pregnant women admitted to the intensive care unit were mostly at the end of the second trimester or in the third trimester of pregnancy. It was observed that COVID-19-associated mortality was high in pregnant women infected with Covid-19 (60%). Moreover, low SpO<sub>2</sub> at admission to the intensive care unit was associated with increased mortality. The most common symptoms observed in pregnant women in our study were consistent with previous studies (Allotey J, et al., 2020; Faraz S, et al., 2022; Hantoushzadeh S, et al., 2020; Sitter M, et al., 2022; Zaigham M, Andersson O. 2020). The main presenting symptom of the non-surviving patients was respiratory failure, while the surviving patients mostly presented with fatigue and headache. The fact that respiratory failure is the major presenting symptom in non-surviving patients shows that it is a serious risk factor for mortality. Perinatal and neonatal deaths were also observed in our study's pregnancy outcomes.

Pregnant women with COVID-19 disease may require intensive care depending on the severity of the disease. During the pandemic period, there has been an increase in the proportion of pregnant women admitted to intensive care units (Allotey J, et al.,2020). A study on pregnant women with COVID-19 reported that 9.6% of the patients were admitted to intensive care units and that most of these patients were in the third trimester of pregnancy. The intensive care unit mortality rate in these patients was 16.4% (10 of 61 patients) (Turan O, et al. 2020). In another study, it was stated that among 385 pregnant women, 17 were admitted to the intensive care unit with one maternal death (Elshafeey F, et al.,2020). Moreover, in a study on 123 COVID-19-positive pregnant women, 30 patients (24.4%) had severe COVID-19 symptoms requiring intensive care unit admission, and 6 of these patients (20%) died (Faraz S, et al.,2022). In two studies reporting higher mortality rates compared to these studies, it was stated that 10 out of 14 and 7 out of 9 patients admitted to ICUs died, respectively (Hantoushzadeh S, et al.,2020; Ríos-Silva M, et al.,2020).

The symptoms caused by COVID-19 disease may vary among pregnant women. They may also lead to the need for intensive care depending on the disease severity. In three studies, 35.2%, 40%, and, 83.6% of the pregnant women admitted to the intensive care units required IMV, respectively (Turan O, et al. 2020; Faraz S, et al.,2022; Elshafeey F, et al. 2020). Our study also found a high mortality rate (60%) and an increased need for IMV (70%), similar to the reported rates in the mentioned studies. Only one of the patients requiring IMV survived. This group of patients admitted to intensive care units due to severe clinical symptoms are observed to have high mortality rates associated with COVID-19-related severe ARDS. Therefore, preventive measures and immunization play a very important role in decreasing the elevated morbidity and mortality risk in the susceptible population of pregnant women. Furthermore, it has been reported in the literature that COVID-19 patients with high levels of IL-6-induced inflammation may benefit from treatment with myo-inositol, and that tocilizumab, an IL-6 receptor inhibitor, can improve oxygenation and clinical outcomes in COVID-19 patients (Bizzarri M, et al.,2020; Bezerra Espinola MS, et al.,2021). In a study conducted in the UK, three postpartum patients admitted to the intensive care unit had intensive care unit stays of 15, 17, and 35 days. Two of these patients required prone positioning. It was stated that none of these patients experienced cytokine storm and all 3 patients were discharged (Morton S, et al.,2021). Two postpartum patients were included in our study. The patient with mild to moderate symptoms was discharged, while the patient presenting with severe symptoms died. Only one patient in the study population received treatment for cytokine storm.

It was shown that in-hospital death, preterm delivery, cesarean section, preeclampsia, placental separation, and disseminated intravascular coagulation (DIC) were statistically significantly more common in pregnant women with COVID-19 infection compared to normal pregnant women. The neonatal mortality rate was reported to range from 0% to 11.7% (Vergara-Merino L, et al.,2021; Litman EA, et al.,2022; Epelboin S, et al.,2021; Antoun L, et al.,2020; Jafari M, et al.,2021). In addition, severe cases are associated with longer hospital stays and intensive care unit admissions (Faraz S, et al.,2022). The rate of cesarean section was higher in patients in our study, and severe COVID-19 infection was associated with an increased risk of cesarean section.

COVID-19 does not only affect the respiratory system. It was shown that COVID-19 may also cause endothelial inflammation, cardiomyopathy, multiorgan dysfunction, neurological syndromes, and hypercoagulation (Behzad S, et al.,2020). It was observed that thrombotic events were more common in these patients and the potential importance of COVID-19-associated venous thromboembolism (VTE) was emphasized (Turan O, et al.,2020; Zaigham M, Andersson O. 2020; Jering KS, et al.,2020; Sebuhyan M, et al.,2020; Thondapu V, et al.,2021). COVID-19 affects many systems, resulting in increased complications in patients. Our cases are consistent with the literature. Maternal death, neonatal death, perinatal death, pulmonary embolism, stillbirth, and preterm delivery were observed in our cases.

Elevation in some laboratory parameters may be associated with poor prognosis in COVID-19 patients. Elevated CRP and ferritin levels were associated with worse COVID-19 in the third trimester of pregnancy (Kim HM, et al.,2022). In the literature, it has been reported that pregnant women infected with COVID-19 have lower or normal lymphocyte percentage and higher CRP, procalcitonin, and D-dimer levels compared to non-pregnant women. CRP, WBC, ferritin, procalcitonin, and D-dimer levels were high in our patients due to severe COVID-19 (Wang Z, et al.,2020; Chen L, et al.,2020). However, these values were not significant between survivors and non-survivors, because all our patients were pregnant and their clinical conditions were severe.

Some factors limited the research. Our study had no control group and only included a limited number of patients admitted to the intensive care unit due to COVID-19 pneumonia. The study was a single-center, retrospective study.

## CONCLUSION

In conclusion, we found that COVID-19-infected pregnant women with severe symptoms have several maternal morbidities and poor obstetric outcomes,

such as prolonged intensive care unit stay, increased mortality, neonatal deaths, and cesarean section. It is important to carefully follow pregnant women in their second and third trimesters of pregnancy and inform them about preventive measures because they are at a high risk of having serious outcomes.

### Acknowledgement

**Ethics Committee Approval:** It was conducted with the approval of Malatya Turgut Ozal University

**Financial Resource/ Sponsor's Role:** No financial support was received for the study.

**Conflict of Interest:** The authors have no conflicts of interest to declare.

### Author Contributions:

**Idea/Concept:** Ahmet AYDIN, Sevgi KUTLUSOY, Erdiñç KOCA **Design:** Ahmet AYDIN **Supervision/Consulting:** Sevgi KUTLUSOY, Erdiñç KOCA **Data Collection and/or Processing:** Ahmet AYDIN, Sevgi KUTLUSOY, Erdiñç KOCA **Analysis and/or Interpretation:** Ahmet AYDIN **Literature Review:** Ahmet AYDIN **Writing of the Article:** Ahmet AYDIN **Critical Review:** Sevgi KUTLUSOY, Erdiñç KOCA **Resources and Funding:** Ahmet AYDIN

### REFERENCES

Allotey, J., Stallings, E., Bonet, M., Yap, M., Chatterjee, S., Kew, T., Debenham, L., Llavall, A. C., Dixit, A., Zhou, D., Balaji, R., Lee, S. I., Qiu, X., Yuan, M., Coomar, D., Sheikh, J., Lawson, H., Ansari, K., van Wely, M., van Leeuwen, E., ... for PregCOV-19 Living Systematic Review Consortium (2020). Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ (Clinical research ed.)*, 370, m3320.

Antoun, L., Taweel, N. E., Ahmed, I., Patni, S., & Honest, H. (2020). Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: A prospective cohort study. *European journal of obstetrics, gynecology, and reproductive biology*, 252, 559–562.

Force, A. D. T., Ranieri, V. M., Rubinfeld, G. D., Thompson, B., Ferguson, N., Caldwell, E., ... & Slutsky, A. S. (2012). Acute respiratory distress syndrome. *Jama*, 307(23), 2526-2533.

Behzad, S., Aghaghazvini, L., Radmard, A. R., & Gholamrezanezhad, A. (2020). Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview. *Clinical imaging*, 66, 35–41.

Bezerra Espinola, M. S., Bertelli, M., Bizzarri, M., Unfer, V., Laganà, A. S., Visconti, B., & Aragona, C. (2021). Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk. *Journal of reproductive immunology*, 144, 103271.

Bizzarri, M., Laganà, A. S., Aragona, D., & Unfer, V. (2020). Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?. *European review for medical and pharmacological sciences*, 24(6), 3426–3432.

Chen, H., Guo, J., Wang, C., Luo, F., Yu, X., Zhang, W., Li, J., Zhao, D., Xu, D., Gong, Q., Liao, J., Yang, H., Hou, W., & Zhang, Y. (2020). Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet (London, England)*, 395(10226), 809–815.

Chen, L., Li, Q., Zheng, D., Jiang, H., Wei, Y., Zou, L., Feng, L., Xiong, G., Sun, G., Wang, H., Zhao, Y., & Qiao, J. (2020). Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. *The New England journal of medicine*, 382(25), e100.

DeBolt, C. A., Bianco, A., Limaye, M. A., Silverstein, J., Penfield, C. A., Roman, A. S., Rosenberg, H. M., Ferrara, L., Lambert, C., Houry, R., Bernstein, P. S., Burd, J., Berghella, V., Kaplowitz, E., Overbey, J. R., & Stone, J. (2021). Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls. *American journal of obstetrics and gynecology*, 224(5), 510.e1–510.e12.

Di Mascio, D., Khalil, A., Saccone, G., Rizzo, G., Buca, D., Liberati, M., Vecchiet, J., Nappi, L., Scambia, G., Berghella, V., & D'Antonio, F. (2020). Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. *American journal of obstetrics & gynecology MFM*, 2(2), 100107.

Ellington, S., Strid, P., Tong, V. T., Woodworth, K., Galang, R. R., Zambrano, L. D., Nahabedian, J., Anderson, K., & Gilboa, S. M. (2020). Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020. *MMWR. Morbidity and mortality weekly report*, 69(25), 769–775.

Elshafeey, F., Magdi, R., Hindi, N., Elshebiny, M., Farrag, N., Mahdy, S., Sabbour, M., Gebriel, S., Nasser, M., Kamel, M., Amir, A., Maher Emara, M., & Nabhan, A. (2020). A systematic scoping review

of COVID-19 during pregnancy and childbirth. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, 150(1), 47–52.

Epelboin, S., Labrosse, J., De Mouzon, J., Fauque, P., Gervoise-Boyer, M. J., Levy, R., Sermondade, N., Hesters, L., Bergère, M., Devienne, C., Jonveaux, P., Ghosn, J., & Pessione, F. (2021). Obstetrical outcomes and maternal morbidities associated with COVID-19 in pregnant women in France: A national retrospective cohort study. *PLoS medicine*, 18(11), e1003857.

Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention (2020). *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*, 41(2), 145–151.

Faraz, S., Aftab, N., Ammar, A., Al Mulai, I., Paulose, L., & Fernandes, S. (2022). An Insight on the Maternal-Fetal Outcomes of Critically Ill Pregnant Women During the Second Wave of COVID-19. *Cureus*, 14(1), e20998.

Hantoushzadeh, S., Shamshirsaz, A. A., Aleyasin, A., Seferovic, M. D., Aski, S. K., Arian, S. E., Pooransari, P., Ghotbizadeh, F., Aalipour, S., Soleimani, Z., Naemi, M., Molaei, B., Ahangari, R., Salehi, M., Oskoei, A. D., Pirozan, P., Darkhaneh, R. F., Laki, M. G., Farani, A. K., Atrak, S., ... Aagaard, K. (2020). Maternal death due to COVID-19. *American journal of obstetrics and gynecology*, 223(1), 109.e1–109.e16.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., ... Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*, 395(10223), 497–506.

Hui, D. S. C., & Zumla, A. (2019). Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. *Infectious disease clinics of North America*, 33(4), 869–889.

Jafari, M., Pormohammad, A., Sheikh Neshin, S. A., Ghorbani, S., Bose, D., Alimohammadi, S., Basirjafari, S., Mohammadi, M., Rasmussen-Ivey, C., Razizadeh, M. H., Nouri-Vaskeh, M., & Zarei, M. (2021). Clinical characteristics and outcomes of pregnant women with COVID-19 and comparison with control patients: A systematic review and meta-analysis. *Reviews in medical virology*, 31(5), 1–16.

Jering, K. S., Claggett, B. L., Cunningham, J. W., Rosenthal, N., Vardeny, O., Greene, M. F., & Solomon, S. D. (2021). Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth

With and Without COVID-19. *JAMA internal medicine*, 181(5), 714–717.

Kim, H. M., Kwon, K. T., Cha, H. H., Seong, W. J., & Kim, M. J. (2022). Prediction of Adverse Outcomes among Women in the Third Trimester of Pregnancy with Coronavirus Disease 2019. *Infection & chemotherapy*, 54(3), 493–503.

Knight, M., Bunch, K., Vousden, N., Morris, E., Simpson, N., Gale, C., O'Brien, P., Quigley, M., Brocklehurst, P., Kurinczuk, J. J., & UK Obstetric Surveillance System SARS-CoV-2 Infection in Pregnancy Collaborative Group (2020). Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. *BMJ (Clinical research ed.)*, 369, m2107.

Litman, E. A., Yin, Y., Nelson, S. J., Capbarat, E., Kerchner, D., & Ahmadzia, H. K. (2022). Adverse perinatal outcomes in a large United States birth cohort during the COVID-19 pandemic. *American journal of obstetrics & gynecology MFM*, 4(3), 100577.

LoMauro, A., & Aliverti, A. (2015). Respiratory physiology of pregnancy: Physiology masterclass. *Breathe (Sheffield, England)*, 11(4), 297–301.

Morton, S., Lamont, H., Silvey, N., Browning, T., Hayes, M., Keays, R., Christie, L., Davies, R., Singh, S., Lockie, C., Sisson, A., Vizcaychipi, M., & Chelwest COVID-19 AICU Consortium (2021). Adult intensive care unit admissions with severe COVID-19 infection following emergency Caesarean section deliveries: A case series. *Journal of the Intensive Care Society*, 22(4), 288–299.

Ríos-Silva, M., Murillo-Zamora, E., Mendoza-Cano, O., Trujillo, X., & Huerta, M. (2020). COVID-19 mortality among pregnant women in Mexico: A retrospective cohort study. *Journal of global health*, 10(2), 020512.

Sebuhyan, M., Mirailles, R., Crichi, B., Frere, C., Bonnin, P., Bergeron-Lafaurie, A., Denis, B., Liegeon, G., Peyrony, O., Farge, D., & Saint-Louis CORE (COVID-19 RESEARCH) group (2020). How to screen and diagnose deep venous thrombosis (DVT) in patients hospitalized for or suspected of COVID-19 infection, outside the intensive care units. *Journal de medecine vasculaire*, 45(6), 334–343.

Sitter, M., Pecks, U., Rüdiger, M., Friedrich, S., Fill Malfertheiner, S., Hein, A., Königbauer, J. T., Becke-Jakob, K., Zöllkau, J., Ramsauer, B., Rathberger, K., Pontones, C. A., Kraft, K., Meybohm, P., Härtel, C., Kranke, P., & Cronos Network (2022). Pregnant and Postpartum Women Requiring Intensive Care Treatment for COVID-19-



First Data from the CRONOS-Registry. *Journal of clinical medicine*, 11(3), 701.

Thondapu, V., Montes, D., Rosovsky, R., Dua, A., McDermott, S., Lu, M. T., Ghoshhajra, B., Hoffmann, U., Gerhard-Herman, M. D., & Hedgire, S. (2021). Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019. *Journal of vascular surgery. Venous and lymphatic disorders*, 9(4), 835–844.e4.

Turan, O., Hakim, A., Dashraath, P., Jeslyn, W. J. L., Wright, A., & Abdul-Kadir, R. (2020). Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: A systematic review. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, 151(1), 7–16.

Vergara-Merino, L., Meza, N., Couve-Pérez, C., Carrasco, C., Ortiz-Muñoz, L., Madrid, E., Bohorquez-Blanco, S., & Pérez-Bracchiglione, J. (2021). Maternal and perinatal outcomes related to COVID-19 and pregnancy: An overview of systematic reviews. *Acta obstetrica et gynecologica Scandinavica*, 100(7), 1200–1218.

Wang, Z., Wang, Z., & Xiong, G. (2020). Clinical characteristics and laboratory results of pregnant women with COVID-19 in Wuhan, China. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, 150(3), 312–317.

Wastnedge, E. A. N., Reynolds, R. M., van Boeckel, S. R., Stock, S. J., Denison, F. C., Maybin, J. A., & Critchley, H. O. D. (2021). Pregnancy and COVID-19. *Physiological reviews*, 101(1), 303–318.

Wong, S. F., Chow, K. M., Leung, T. N., Ng, W. F., Ng, T. K., Shek, C. C., Ng, P. C., Lam, P. W., Ho, L. C., To, W. W., Lai, S. T., Yan, W. W., & Tan, P. Y. (2004). Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. *American journal of obstetrics and gynecology*, 191(1), 292–297.

Zaigham, M., & Andersson, O. (2020). Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. *Acta obstetrica et gynecologica Scandinavica*, 99(7), 823–829.

Zhonghua Liu Xing Bing Xue Za Zhi. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. 2020; 41: 145-151.